SAM
CPRX

Symphony Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Symphony Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-55,126
Closed -$165K – 432
2015
Q3 		$165K Buy
55,126
+34,337
+165% +$148K 0.02% 420
2015
Q2 		$85K Buy
+20,789
New +$82.9K 0.01% 411

Other funds holding CPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Symphony Asset Management's CPRX Position: Q4 2015 in Review

Symphony Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2015, closing a stake of 55,126 shares — an estimated $165K sold.

Symphony Asset Management first reported a position in CPRX in Q2 2015 and held it in 2 quarters. The position peaked at $165K in Q3 2015. 85 funds tracked by Wall St. Rank hold CPRX as of Q4 2015.

  • Symphony Asset Management reported no remaining Catalyst Pharmaceutical position as of Q4 2015 after selling out during the quarter.
  • Symphony Asset Management sold 55,126 Catalyst Pharmaceutical shares in Q4 2015, an estimated $165K.
  • Symphony Asset Management first reported a position in Catalyst Pharmaceutical in Q2 2015 and held it in 2 quarters.
  • Symphony Asset Management's Catalyst Pharmaceutical position peaked at $165K in Q3 2015.
  • 85 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2015.

Based on Symphony Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.